IL240183A - Non-Alcoholic Obesity Preparation (nafld) - Google Patents

Non-Alcoholic Obesity Preparation (nafld)

Info

Publication number
IL240183A
IL240183A IL240183A IL24018315A IL240183A IL 240183 A IL240183 A IL 240183A IL 240183 A IL240183 A IL 240183A IL 24018315 A IL24018315 A IL 24018315A IL 240183 A IL240183 A IL 240183A
Authority
IL
Israel
Prior art keywords
nafld
composition
liver disease
fatty liver
nonalcoholic fatty
Prior art date
Application number
IL240183A
Other languages
English (en)
Hebrew (he)
Other versions
IL240183A0 (en
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of IL240183A0 publication Critical patent/IL240183A0/en
Publication of IL240183A publication Critical patent/IL240183A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL240183A 2013-04-22 2015-07-28 Non-Alcoholic Obesity Preparation (nafld) IL240183A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1468MU2013 IN2013MU01468A (enExample) 2013-04-22 2013-06-25
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)

Publications (2)

Publication Number Publication Date
IL240183A0 IL240183A0 (en) 2015-09-24
IL240183A true IL240183A (en) 2016-08-31

Family

ID=49253372

Family Applications (2)

Application Number Title Priority Date Filing Date
IL240183A IL240183A (en) 2013-04-22 2015-07-28 Non-Alcoholic Obesity Preparation (nafld)
IL247231A IL247231A (en) 2013-04-22 2016-08-11 Preparation for the treatment of non-alcoholic obesity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL247231A IL247231A (en) 2013-04-22 2016-08-11 Preparation for the treatment of non-alcoholic obesity

Country Status (21)

Country Link
US (3) US20160166539A1 (enExample)
EP (1) EP2988736A1 (enExample)
JP (1) JP6246895B2 (enExample)
KR (1) KR101617812B1 (enExample)
CN (1) CN105377246B (enExample)
AP (1) AP2015008674A0 (enExample)
AU (1) AU2013387996B2 (enExample)
BR (1) BR112015020600A2 (enExample)
CA (1) CA2900435C (enExample)
EA (1) EA201592020A1 (enExample)
GE (1) GEP201706663B (enExample)
HK (1) HK1214968A1 (enExample)
IL (2) IL240183A (enExample)
IN (1) IN2013MU01468A (enExample)
MA (1) MA38385A1 (enExample)
MX (1) MX346943B (enExample)
MY (1) MY180160A (enExample)
PH (1) PH12015501795A1 (enExample)
SG (1) SG11201506218UA (enExample)
UA (1) UA114360C2 (enExample)
WO (1) WO2014174524A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104869A1 (en) 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
IN2013MU01468A (enExample) 2013-04-22 2015-04-17 Cadila Healthcare Ltd
WO2014195967A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enExample) * 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN117137917A (zh) * 2016-04-22 2023-12-01 景凯生物科技股份有限公司 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用
BR112019011740A2 (pt) 2016-12-09 2019-10-29 Cadila Healthcare Limited composição farmacêutica e método para o tratamento de colangite biliar primária
KR20240091322A (ko) 2017-03-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
JP7479278B2 (ja) * 2017-10-06 2024-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ａｃｃ阻害剤を含む併用療法
CN109675016A (zh) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 非酒精性脂肪性肝病的治疗药物
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US12201609B2 (en) * 2018-12-18 2025-01-21 Zydus Lifesciences Limited Saroglitazar for the treatment of hepatocellular carcinoma
US20220175721A1 (en) * 2019-02-13 2022-06-09 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
US20250281438A1 (en) * 2020-12-18 2025-09-11 Societe Des Produits Nestle S.A. Compositions and methods using at least one glycine or derivative thereof and/or at least one n-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol
WO2022246243A1 (en) * 2021-05-21 2022-11-24 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
DE69331010D1 (de) 1992-07-03 2001-11-29 Smithkline Beecham Plc Benzoxazol- und benzothiazol-derivate als arzneimittel
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
BR9608040B1 (pt) 1995-04-28 2010-02-23 composto taxàide pentacÍclico.
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP1082313A1 (en) 1998-05-27 2001-03-14 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023417A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
MEP32408A (en) 2000-01-19 2010-10-10 Cadila Healthcare Ltd Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20070051626A1 (en) 2003-09-26 2007-03-08 Chiho Itou Cataphoresis apparatus cataphoresis method, and detection method for organism-related material using the apparatus and the method
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
CA2623762A1 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Modulation of glucagon receptor expression
US7737266B2 (en) * 2006-09-18 2010-06-15 Board Of Regents, The University Of Texas System RNAi modulation of SCAP and therapeutics uses thereof
JP2008184429A (ja) * 2007-01-30 2008-08-14 Japan Health Science Foundation 肝臓トリグリセリド濃度低下剤
CN102647982B (zh) 2009-11-26 2014-10-15 基恩菲特公司 使用1,3-二苯基丙-2-烯-1-酮衍生物治疗肝脏疾患
CA2814194A1 (en) 2010-10-12 2012-04-19 The Johns Hopkins University Antitussive compositions comprising memantine
WO2012104869A1 (en) 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy
IN2013MU01468A (enExample) 2013-04-22 2015-04-17 Cadila Healthcare Ltd
WO2014195967A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02828A (enExample) 2013-08-29 2015-07-03 Cadila Healthcare Ltd
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts

Also Published As

Publication number Publication date
KR20150118990A (ko) 2015-10-23
KR101617812B1 (ko) 2016-05-03
CA2900435A1 (en) 2014-10-30
IL240183A0 (en) 2015-09-24
UA114360C2 (uk) 2017-05-25
MX2015010769A (es) 2015-11-26
WO2014174524A8 (en) 2015-10-01
CN105377246A (zh) 2016-03-02
US20160166539A1 (en) 2016-06-16
WO2014174524A1 (en) 2014-10-30
IL247231A (en) 2017-03-30
AU2013387996B2 (en) 2015-12-10
JP6246895B2 (ja) 2017-12-13
US20170087127A1 (en) 2017-03-30
GEP201706663B (en) 2017-05-10
AU2013387996A1 (en) 2015-09-24
AP2015008674A0 (en) 2015-08-31
PH12015501795A1 (en) 2015-11-09
CA2900435C (en) 2017-02-14
MA38385A1 (fr) 2017-09-29
EA201592020A1 (ru) 2016-05-31
EP2988736A1 (en) 2016-03-02
SG11201506218UA (en) 2015-09-29
BR112015020600A2 (pt) 2017-07-18
MX346943B (es) 2017-04-06
CN105377246B (zh) 2018-03-20
JP2016515608A (ja) 2016-05-30
US20180185330A1 (en) 2018-07-05
MY180160A (en) 2020-11-23
HK1214968A1 (zh) 2016-08-12
IN2013MU01468A (enExample) 2015-04-17
US9814697B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
IL240183A (en) Non-Alcoholic Obesity Preparation (nafld)
IL271509B (en) Compositions and methods for the multiple synthesis of nucleic acids
ZA202005525B (en) Antibody formulations
IL279395A (en) A vaccine
ZA201506441B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
IL243481B (en) A drug for the treatment of non-alcoholic fatty liver disease
IL244712B (en) Anti- pdl1 antibody compositions
PT3024484T (pt) Composições de anticorpo estabilizadas
PL2839750T3 (pl) Kompozycja tłuszczowa
IL245461A0 (en) A useful preparation for improving female fertility
EP2952194A4 (en) EMULSION COMPOSITION
PL2956010T5 (pl) Kompozycja tłuszczów
ZA201600241B (en) Water-resistant composition
GB201305984D0 (en) Mechanical linkage
SG11201507181YA (en) Method for the treatment of fatty liver disease
GB201311067D0 (en) Dual curable composition
GB2535880B (en) Two-part set-delayed cement compositions
EP3000867A4 (en) Fat composition
SG11201604345VA (en) Phenol composition
GB201509781D0 (en) Non-alcoholic fatty liver disease
GB201311814D0 (en) Soap or syndet composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees